WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 575090
CAS#: 98845-64-8 (lysine)
Description: Mafosfamide-lysine is a salt of cyclophosphamide.
MedKoo Cat#: 575090
CAS#: 98845-64-8 (lysine)
Chemical Formula: C15H33Cl2N4O7PS2
Exact Mass: 546.0905
Molecular Weight: 547.44
Elemental Analysis: C, 32.91; H, 6.08; Cl, 12.95; N, 10.23; O, 20.46; P, 5.66; S, 11.71
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Asta 7654; Asta Z 7654; Mafosfamide-lysine
IUPAC/Chemical Name: L-lysine compound with 2-(((2S,4S)-2-(bis(2-chloroethyl)amino)-2-oxido-1,3,2-oxazaphosphinan-4-yl)thio)ethane-1-sulfonic acid (1:1)
InChi Key: DYLRFXGKCIFZAH-NNDOHRJVSA-N
InChi Code: InChI=1S/C9H19Cl2N2O5PS2.C6H14N2O2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17;7-4-2-1-3-5(8)6(9)10/h9H,1-8H2,(H,12,14)(H,15,16,17);5H,1-4,7-8H2,(H,9,10)/t9-,19-;5-/m00/s1
SMILES Code: NCCCC[C@H](N)C(=O)O.OS(=O)(=O)CCS[C@H]1CCO[P@@](=O)(N1)N(CCCl)CCCl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 547.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Mazur L, Opydo-Chanek M, Stojak M, Wojcieszek K. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res. 2012 Jul;32(7):2783-9. PMID: 22753738.
2. Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr;50(4):757-60. doi: 10.1002/pbc.21330. PMID: 17849472; PMCID: PMC2975705.